Latest Enzyme (MLN) News Update

Deep Dive

1. @enzymefinance: Announcing Launch Partnership with Rayls bullish

"Enzyme is joining @RaylsLabs as a launch partner 💪Onyx & Myso will be live on Rayls from day one. Institutional-grade tokenized fund infrastructure to the network." – @enzymefinance (X followers not provided · 8 May 2026 10:51 PM UTC) View original post What this means: This is bullish for MLN because it demonstrates active business development and expands the protocol's reach into institutional tokenized funds, which could drive future usage and fee burns.

2. Binance News: Binance Confirms MLN Delisting, Price Falls 18% bearish

"Following the announcement, MLN fell 18%... Spot trading for these tokens ends on May 27, 2026." – Binance News (16 May 2026 01:00 PM UTC) View original post What this means: This is bearish for MLN because losing support from the world's largest exchange severely damages liquidity, accessibility, and investor confidence, leading to immediate sell-offs.

3. CoinMarketCap: Bybit to Delist MLN Perpetual Futures on June 26 bearish

"Bybit... will delist perpetual futures contracts for... Enzyme (MLN)... at 11:30 a.m. UTC on June 26." – CoinMarketCap Community (24 June 2026 12:20 PM UTC) View original post What this means: This is bearish for MLN because it signals a second major exchange is removing leveraged trading, further concentrating sell-side pressure and reducing market depth for traders.

Conclusion

The consensus on MLN is bearish, dominated by the severe impact of consecutive exchange delistings which overshadow its partnership progress. The immediate focus for traders is managing the liquidity crunch. Watch the trading volume and liquidity on alternative exchanges post-June 26 to gauge if a new support level can form.

Deep Dive

1. Bybit Delists MLN Futures (24 June 2026)

Overview: Bybit announced it will delist perpetual futures contracts for Enzyme (MLN), Solv (SOLV), and Mobox (MBOX) on June 26, 2026. All open MLNUSDT positions will be automatically closed at the market price at 11:30 a.m. UTC. Exchanges typically take such action after periodic reviews of liquidity, trading volume, and project development. What this means: This is bearish for MLN because it removes a major venue for leveraged trading, which can reduce liquidity and increase volatility as traders adjust. It signals that the contract no longer meets the exchange's performance standards, potentially affecting broader market sentiment. (CoinMarketCap)

2. Binance Removes MLN from Spot Trading (13 May 2026)

Overview: Binance confirmed the full delisting of MLN from all spot, margin, and futures trading, with services ending on May 27, 2026. The token had been placed on a "Monitoring Tag" in April, foreshadowing this action. Following the announcement, MLN's price fell 18%. What this means: This is strongly bearish as it drastically reduces liquidity and accessibility for a major investor base, often leading to sustained selling pressure and reputational damage. It underscores the project's challenge in meeting the exchange's criteria for trading volume and development activity. (CoinMarketCap)

3. Enzyme Joins Rayls as Launch Partner (8 May 2026)

Overview: Enzyme announced a partnership with Rayls Labs to bring its institutional-grade tokenized fund infrastructure, Onyx and Myso, to the Rayls network from day one. This expands Enzyme's reach into a new ecosystem for on-chain asset management. What this means: This is bullish for MLN as it demonstrates continued technical development and ecosystem integration, potentially driving future protocol usage and fee generation. It shows the project is actively building despite exchange-related headwinds. (Enzyme)

Conclusion

MLN is caught between contracting exchange support and ongoing ecosystem development, creating a high-contrast risk/reward profile. Will its core technology partnerships and usage ultimately outweigh the loss of major trading venues?

Deep Dive

1. Native Integration with Canton Network (Q3 2026)

Overview: Enzyme announced it joined the Canton Foundation on 22 May 2026 and is preparing to bring its core products, Onyx (tokenized fund infrastructure) and Myso (structured products), natively to the Canton Network. This is a planned integration for the third quarter of 2026. The Canton Network is a privacy-enabled, interoperable blockchain platform designed for institutional finance, suggesting Enzyme is targeting deeper integration with traditional capital markets.

What this means: This is bullish for MLN because it could significantly expand Enzyme's addressable market by connecting its asset management tools to a network built for large financial institutions. Successful integration may drive new vault creation and assets under management (AUM), increasing protocol fee revenue and the subsequent burn of MLN tokens. The key risk is execution–delivering a seamless integration on a new, complex network by the stated timeline.

Conclusion

Enzyme's immediate roadmap is focused on expanding its institutional footprint through a strategic integration with the Canton Network, aiming to unlock new use cases in tokenized finance. Will successful on-chain adoption on Canton be the catalyst needed to offset its recent exchange delistings and reinvigorate network activity?

Deep Dive

1. Joins Canton Network (22 May 2026)

Overview: Enzyme announced it has joined the Canton Foundation. This is a strategic move to integrate its infrastructure into a network designed for institutional finance, with plans to bring its Onyx and Myso products natively to the Canton Network in the third quarter of 2026.

This partnership signifies a focus on interoperability and serving regulated financial institutions. The Canton Network is a privacy-enabled, interoperable blockchain network, suggesting Enzyme is adapting its technology for environments with strict compliance requirements. The update is about preparing for deployment rather than a public code release.

What this means: This is bullish for MLN because it demonstrates serious pursuit of institutional adoption, which could significantly increase the platform's usage and the demand for its token. However, the actual technical integration and code changes are still forthcoming. (Enzyme)

2. Partners with Rayls as Launch Partner (8 May 2026)

Overview: Enzyme integrated with Rayls as a launch partner, making its Onyx (tokenized fund infrastructure) and Myso (on-chain options protocol) available on the Rayls network from its first day of operation.

This is an expansion of Enzyme's modular infrastructure to another blockchain ecosystem. It involves technical work to ensure compatibility, allowing fund managers on Rayls to access Enzyme's tools. The announcement highlights the project's strategy of being deployable across multiple networks.

What this means: This is neutral-to-bullish for MLN as it expands the protocol's potential user base and utility. A wider reach can drive more fee generation, which benefits the token's burn mechanics, but the immediate impact depends on Rayls' own adoption. (Enzyme)

3. Conducts Onyx Workshop at EthCC (2 July 2025)

Overview: The Enzyme development team held a workshop focused on Enzyme.Onyx during the EthCC conference in July 2025. This indicates ongoing, active development and refinement of its core product suite.

While not a code commit log, such workshops are where core architecture decisions and feature roadmaps are often discussed. It signals that the team is engaged with the developer community and iterating on its technology, even if the specific code changes aren't publicly detailed in the provided news.

What this means: This is neutral for MLN as it reflects continued development activity, which is essential for long-term health. However, without specific feature releases or audit results, it's a signal of progress rather than a direct catalyst. (Enzyme)

Conclusion

Enzyme's latest developments show a clear pivot towards multi-network deployment and institutional partnerships, building the rails for tokenized finance rather than publishing frequent public code updates. Will the upcoming Q3 Canton Network integration deliver the technical proof to match its strategic ambition?